Phaseline

Companies › Medipost

Medipost: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 3; Immunology, Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CARTISTEM®
Allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) combined
–Phase 3Knee Cartilage DefectsJun 2029
SMUP-IA-01 (low-dose)
Human umbilical cord blood-derived mesenchymal stem cells
–Phase 2Knee OsteoarthritisMar 2027
PNEUMOSTEM®
Human umbilical cord blood-derived mesenchymal stem cells
–Phase 2Bronchopulmonary DysplasiaJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06798727SMUP-IA-01 (low-dose)Phase 2Knee OsteoarthritisImmunologyMar 2027
NCT06798727SMUP-IA-01 (low-dose)Phase 2Knee OsteoarthritisImmunologyMar 2027
NCT04003857PNEUMOSTEM®Phase 2Bronchopulmonary DysplasiaOtherJun 2027
NCT07339111CARTISTEM®Phase 3Knee Cartilage DefectsImmunologyJun 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Nature Cell Throne Biotechnologies Cellcolabs Clinical SPV EHL Bio TBF Genie Tissulaire

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.